TY - JOUR
T1 - Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma
AU - Hauser, Stefan
AU - Wulfken, Lena M.
AU - Holdenrieder, Stefan
AU - Moritz, Rudolf
AU - Ohlmann, Carsten Henning
AU - Jung, Volker
AU - Becker, Frank
AU - Herrmann, Edwin
AU - Walgenbach-Brünagel, Gisela
AU - von Ruecker, Alexander
AU - Müller, Stefan C.
AU - Ellinger, Jörg
N1 - Funding Information:
The study was supported by a research grant to Jörg Ellinger from the Deutsche Forschungsgemeinschaft ( EL-623/1-1 ). The collection of serum samples in Bonn was performed within the framework of the Biobank of the CIO Köln/Bonn.
PY - 2012/8
Y1 - 2012/8
N2 - Introduction: Emerging evidence suggest that microRNAs could serve as non-invasive biomarker for cancer patients. Our study was designed to analyze circulating serum microRNAs in patients with renal cell carcinoma (RCC). Materials and methods: Serum RNA was isolated from patients with clear cell RCC (ccRCC) and non-malignant disease; an artificial microRNA (cel-miR-39) was spiked-in prior the isolation procedure to control isolation efficiency. The levels of miR-26a-2*, miR-191, miR-337-3p and miR-378 in serum were determined using quantitative real-time PCR; the microRNA levels were normalized to cel-miR-39. Results: First, miR-26a-2*, miR-191, miR-337-3p and miR-378 were quantified in serum of each 25 patients with ccRCC and non-malignant disease. The level of miR-378 was significantly increased in ccRCC patients, and thus chosen for validation. The analysis of miR-378 in the validation cohort with 117 RCC patients and 123 control subjects did not confirm a different level of miR-378. Also, miR-378 was not correlated to pT-stage, lymph node/distant metastasis, vascular invasion and Fuhrman grade. Conclusions: The analysis of circulating serum levels of miR-26a-2*, miR-191, miR-337-3p and miR-378 is unlikely to provide helpful diagnostic/prognostic information in RCC patients.
AB - Introduction: Emerging evidence suggest that microRNAs could serve as non-invasive biomarker for cancer patients. Our study was designed to analyze circulating serum microRNAs in patients with renal cell carcinoma (RCC). Materials and methods: Serum RNA was isolated from patients with clear cell RCC (ccRCC) and non-malignant disease; an artificial microRNA (cel-miR-39) was spiked-in prior the isolation procedure to control isolation efficiency. The levels of miR-26a-2*, miR-191, miR-337-3p and miR-378 in serum were determined using quantitative real-time PCR; the microRNA levels were normalized to cel-miR-39. Results: First, miR-26a-2*, miR-191, miR-337-3p and miR-378 were quantified in serum of each 25 patients with ccRCC and non-malignant disease. The level of miR-378 was significantly increased in ccRCC patients, and thus chosen for validation. The analysis of miR-378 in the validation cohort with 117 RCC patients and 123 control subjects did not confirm a different level of miR-378. Also, miR-378 was not correlated to pT-stage, lymph node/distant metastasis, vascular invasion and Fuhrman grade. Conclusions: The analysis of circulating serum levels of miR-26a-2*, miR-191, miR-337-3p and miR-378 is unlikely to provide helpful diagnostic/prognostic information in RCC patients.
KW - Biomarkers
KW - Diagnosis
KW - MiR-378
KW - MicroRNA
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84863465388&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2012.04.001
DO - 10.1016/j.canep.2012.04.001
M3 - Article
C2 - 22542158
AN - SCOPUS:84863465388
SN - 1877-7821
VL - 36
SP - 391
EP - 394
JO - Cancer Epidemiology
JF - Cancer Epidemiology
IS - 4
ER -
